Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon (RAY-GENE)

Vasospasm is a transient contraction causing a decrease in caliber of a vessel and thus a decrease in vascularization in a vascular territory leading to suffering of tissue in the sector concerned. Vasospasm-related diseases have different clinical presentations such as migraine, spastic angina, hypertension related to vasospasm or primary Raynaud's phenomenon (RP). These diseases have few therapeutic methods due to poorly understood pathophysiology. For migraine and angina, the vascular exploration is problematic unlike for primary Raynaud's phenomenon (RP).

Primary Raynaud's phenomenon (RP) is a common peripheral vascular disease to cold with an estimated prevalence between 5-9 % of the general population. It is the expression of an extreme vasospasm microcirculation of the extremities linked to hypersensitivity to cold and that is clinically expressed by the occurrence of syncope stages where the fingers are anesthetized and white, followed by a stage with hyperemic restaining .

The objective of our study is to identify new metabolic pathways involved in vasospasm in order to consider new specific treatments, currently lacking.

The identification of these pathways will be made by the detection of genetic abnormalities causing vasospasm in Raynaud's phenomenon. This disease is a perfectly appropriate model to study vasospasm by its high frequency in the population, its hereditary nature and simple diagnosis. The powerful current genetic strategies will be applied to this model (exome sequencing combined to family connection analysis).

Study Overview

• Status: Completed
• Conditions: Primary Raynaud's Phenomenon (PR); Genetic Mutations Causing PR; Study of Patients and Their Relatives (With or Without Primary PR)
• Intervention / Treatment: Genetic: Demonstration of genetic mutations causing Raynaud's phenomenon

Detailed Description

Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.

In all participating centers, there will be a recruitment of index cases without family screening to form a series of cases that will validate the results obtained in family forms.

The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family.

In all centers, relatives of included Index cases, agreeing to participate in this research, will be enrolled and followed.

Nantes University Hospital is the only center to perform a cold test (for reasons of availability of the technique) but this test will be reserved for patients whose diagnosis of primary Raynaud's phenomenon would be doubtful. Exposed identified relatives, agreeing to participate in this research, will all be included and followed in their enrollment center.

• Study Type: Interventional
• Enrollment (Actual): 258
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Angers, France, 49033 Angers Cedex 01
    • CHU Angers - Service d'Explorations vasculaires
  • Brest, France, 29609 Brest Cedex 2
    • CHRU HOPITAL CAVALE BLANCHE - Service de Médecine vasculaire
  • La Roche sur Yon, France, 85925 La Roche/Yon Cedex 9
    • CHD La Roche sur Yon - Service Angéiologie
  • Nantes, France, 44000
    • CHU de NANTES - Service de Médecine Interne
  • Rennes, France, 35203 Rennes Cedex 2
    • C.H.R. HOPITAL SUD - Service de Médecine interne
  • Saint Nazaire, France, 44600
    • CH Saint Nazaire

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Major Subject (age ≥ 18 years)
• Index case with all the diagnostic criteria for primary Raynaud phenomenon, according to current recommendations OR Related index case (relatives' patients) with or without a primary Raynaud phenomenon.
• Written consent to participate in the study
• Written consent to participate in the collection of biological samples

Exclusion criteria:

• Subjects who have expressed their inability or refusal to sign an informed consent,
• Index case with a secondary Raynaud phenomenon (suspected by clinical examination and confirmed by capillaroscopy and laboratory tests: antinuclear antibody, abnormalities of capillaroscopy mégacapillaire dystrophy or other major deviation).

(Criterion not applicable to related parties, i.e. family members of Index cases)

- Pregnant Woman.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Patient with Raynaud's phenomenon

Genetic: Demonstration of genetic mutations causing Raynaud's phenomenon; Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm. Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases. The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family.; Other Names: Recruitment of familial forms of Raynaud phenomenon (patients with primary; Raynaud phenomenon and their relatives) to perform genetic analysis of; exome sequencing type combined with an analysis of family bonding.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To identify number of genes involved in vasospasm of primary Raynaud's phenomenon (RP) and determine the genetic cause of primary RP	Patients with primary Raynaud's phenomenon and their relatives will be recruited to establish familial forms of Raynaud's phenomenon. This will allow perform genetic analysis using new approaches to genetic broadband (exome sequencing analysis + linkage analysis). This approach will allow specify which chromosomal regions are shared only by affected individuals, and identify new candidate genes	36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine number of phenotypes associated to genotype of primary Raynaud's phenomenon	Based on the identified genes in different families, a descriptive analysis will allow associate them with different RP phenotypes (isolated RP or RP associated with migraines, angina or hypertension) and risk factors.	36 months

Collaborators and Investigators

• Sponsor: Nantes University Hospital
• Investigators: Study Director: Marc-Antoine Pistorius, Prof, University Hospital of Nantes; Principal Investigator: Marc-Antoine Pistorius, Prof, University Hospital of Nantes; Principal Investigator: Luc Bressollette, Prof, University Hospital of Brest; Principal Investigator: Patrick Jégo, Prof, University Hospital of Rennes; Principal Investigator: Samir Henni, Dr, University Hospital of Angers; Principal Investigator: Jean-Manuel Kubina, Dr, Hospital of La Roche/Yon; Principal Investigator: Pierre Plissonneau Duquene, Dr, Hospital of St Nazaire

Study record dates

Study Major Dates

• Study Start (Actual): October 13, 2014
• Primary Completion (Actual): June 10, 2020
• Study Completion (Actual): June 10, 2020

Study Registration Dates

• First Submitted: July 15, 2014
• First Submitted That Met QC Criteria: July 24, 2014
• First Posted (Estimate): July 29, 2014

Study Record Updates

• Last Update Posted (Actual): June 24, 2020
• Last Update Submitted That Met QC Criteria: June 22, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: Raynaud's phenomenon, Vasospasm, Genetics
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Peripheral Vascular Diseases; Raynaud Disease
• Other Study ID Numbers: RC14_0086; 2014-A00470-47 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No